News & Updates

Back to All

Kedalion Therapeutics Names Ehud Ivri Chief Technology Officer

Menlo Park, CA, August 1, 2016 – Kedalion Therapeutics, Inc., an early-stage company focused on the development and commercialization of topical ophthalmology therapies based on its proprietary AcuStream™ platform, today named Ehud Ivri as Chief Technology Officer.

“Ehud has a strong record of innovation and success in the fields of microfluidics and drug delivery, and we are very pleased to welcome him to this important role. The AcuStream technology platform is based on core technology and IP that Ehud brought to the table,” said Mark Blumenkranz, M.D., M.M.S., Executive Chairman, Kedalion. “His expertise in this area is unsurpassed and we look forward to his contributions to advancing the AcuStream platform and generating additional IP to shore up our patent portfolio as we move toward a commercialization pathway.”

Mr. Ivri holds over 40 patents related to medical devices and drug delivery systems. An electro-mechanical engineer, his work is focused mainly in the field of drug delivery and pharmaceuticals. Prior to Kedalion, Mr. Ivri developed a new micro-dispensing technology for the production of DNA micro-arrays that was licensed to BioDot Inc. His work in the medical device field began with his founding of Aerogen, now a leading producer of nebulizers for inhalation drug delivery based on his invention. Mr. Ivri holds degrees in mechanical engineering from the Technion-Israel Institute of Technology.


About Kedalion Therapeutics
Kedalion Therapeutics is a venture-backed, early-stage biotechnology company whose mission is to bring to market transformative topical ophthalmic therapies for new and existing indications. Kedalion’s proprietary AcuStream platform technology delivers topical drugs to the eye in a precise and accurate manner that enables comparable effect with up to an 80% reduction in dose compared to standard eye drops. Kedalion is based in Menlo Park, CA. For more information, visit


Download a PDF version of this press release >